Patel此前曾担任Ironshore Pharmaceuticals的首席法务官，在制药行业拥有超过20年的法律和合规经验。他的任命正值Cingulate计划为CTx-1301申请监管批准，这是一种用于注意力缺陷多动障碍的右旋甲基苯丙胺盐酸盐制剂。

Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across every stage of drug development, launch, and commercialization ...

Anterior cingulate cortex is important in monitoring action for new challenges. We recorded neuron activity in the anterior cingulate sulcus of macaques while they performed a sequential problem ...

NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed ...

Cingulate Inc. has secured $5 million in net proceeds through a financing deal structured as a non-convertible, unsecured promissory note valued at $5.48 million, which will accrue interest at 9% ...

Cingulate's progress with CTx-1301 is a key factor in H.C. Wainwright's updated price target. The firm's analyst commented on the successful completion of the clinical program and the upcoming ...

Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...

View Cingulate, Inc. CING stock quote prices, financial information, real-time forecasts, and company news from CNN.

Cingulate Inc. CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 ...

Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned once ...

Cingulate's market value nearly quadrupled Friday, extending a rally sparked early Thursday when the biopharmaceutical company said it got a European patent for its treatment for attention deficit ...